Effect of a Lipid-Lowering Nutraceutical on Pulse-Wave-Velocity in Hypercholesterolemic Patients with or without Chronic Kidney Disease

A. Cicero, A. Parini, M. Rosticci, Barbara Brancaleoni, G. Derosa, E. Grandi, C. Borghi
{"title":"Effect of a Lipid-Lowering Nutraceutical on Pulse-Wave-Velocity in Hypercholesterolemic Patients with or without Chronic Kidney Disease","authors":"A. Cicero, A. Parini, M. Rosticci, Barbara Brancaleoni, G. Derosa, E. Grandi, C. Borghi","doi":"10.2174/1876526201305010018","DOIUrl":null,"url":null,"abstract":"The recent literature has put a large interest on nutraceuticals with lipid lowering activity for the management of moderate cholesterolemia in subjects with mildly increased cardiovascular disease risk. The aim of our study was to evaluate the middle-term effect of a combined lipid-lowering nutraceutical on lipid parameters and aortic stiffness. For this study we consecutively enrolled 40 moderately hypercholesterolemic outpatients with mild-to-moderate chronic kidney disease (CKD) and 40 cross-matched hypercholesterolemic subjects without CKD. All the patient were treated daily with a combined nutraceutical containing red yeast rice (3 mg monacolin K) and berberine (500 mg). At the baseline and after 6 months of treatment we measured blood pressure, pulse wave velocity (PWV) and ematochemistry parameters. No significant change has been observed during the study in both groups regarding body mass index, blood pressure, liver transaminases, creatinin-phosfokinase and eGFR. In non CKD patients TC improved by (-21,6%), LDL-Cholesterol by (-24,2%), non HDL-Cholesterol (-24,0%) and TG (- 20,8%). In CKD patients TC improved by (-21,1%), LDL-Cholesterol by (-23,7%), non HDL-Cholesterol (-23,9%) and TG (- 20,4%). No difference among groups has been observed regarding the effects on lipid metabolism. The PWV has significantly improved in both groups (p<0.01) without differences between groups. In summary, a combined lipid-lowering nutraceutical improved lipid pattern and PWV in both non CKD and mild-to-","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":"85 1","pages":"18-22"},"PeriodicalIF":0.0000,"publicationDate":"2013-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Hypertension Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876526201305010018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 14

Abstract

The recent literature has put a large interest on nutraceuticals with lipid lowering activity for the management of moderate cholesterolemia in subjects with mildly increased cardiovascular disease risk. The aim of our study was to evaluate the middle-term effect of a combined lipid-lowering nutraceutical on lipid parameters and aortic stiffness. For this study we consecutively enrolled 40 moderately hypercholesterolemic outpatients with mild-to-moderate chronic kidney disease (CKD) and 40 cross-matched hypercholesterolemic subjects without CKD. All the patient were treated daily with a combined nutraceutical containing red yeast rice (3 mg monacolin K) and berberine (500 mg). At the baseline and after 6 months of treatment we measured blood pressure, pulse wave velocity (PWV) and ematochemistry parameters. No significant change has been observed during the study in both groups regarding body mass index, blood pressure, liver transaminases, creatinin-phosfokinase and eGFR. In non CKD patients TC improved by (-21,6%), LDL-Cholesterol by (-24,2%), non HDL-Cholesterol (-24,0%) and TG (- 20,8%). In CKD patients TC improved by (-21,1%), LDL-Cholesterol by (-23,7%), non HDL-Cholesterol (-23,9%) and TG (- 20,4%). No difference among groups has been observed regarding the effects on lipid metabolism. The PWV has significantly improved in both groups (p<0.01) without differences between groups. In summary, a combined lipid-lowering nutraceutical improved lipid pattern and PWV in both non CKD and mild-to-
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
降脂营养品对伴或不伴慢性肾病的高胆固醇血症患者脉搏波速度的影响
最近的文献对具有降脂活性的营养保健品在轻度增加心血管疾病风险的受试者中管理中度胆固醇血症有很大的兴趣。本研究的目的是评估联合降脂营养食品对血脂参数和主动脉僵硬度的中期影响。在这项研究中,我们连续招募了40名患有轻度至中度慢性肾脏疾病(CKD)的中度高胆固醇血症门诊患者和40名无CKD的交叉匹配高胆固醇血症患者。所有患者每天服用含有红曲米(3毫克莫那可林K)和小檗碱(500毫克)的联合营养保健品。在基线和治疗6个月后,我们测量了血压、脉搏波速度(PWV)和肌肉化学参数。在研究期间,两组在体重指数、血压、肝转氨酶、肌酐-磷酸酶和eGFR方面均未观察到显著变化。在非CKD患者中,TC改善(- 21.6%),ldl -胆固醇改善(- 24.2%),非hdl -胆固醇改善(- 24.0%),TG改善(- 20.8%)。CKD患者TC改善(- 21.1%),ldl -胆固醇改善(- 23.7%),非hdl -胆固醇改善(- 23.9%),TG改善(- 20.4%)。在脂质代谢的影响方面,各组之间没有观察到差异。两组患者PWV均有显著改善(p<0.01),两组间差异无统计学意义。综上所述,联合降脂营养品改善了非CKD和轻度至中度CKD患者的脂质模式和PWV
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Open Hypertension Journal
Open Hypertension Journal Medicine-Cardiology and Cardiovascular Medicine
自引率
0.00%
发文量
0
期刊最新文献
Implementation of a Resistant Hypertension Control Program in a Low-income Primary Care Setting in a High-Income Country: Lessons Learned and Global Applicability Troponin and B-type Natriuretic Peptides Biomarkers in the Management of Hypertension Hypertension in end-stage kidney disease Confirming a Diagnosis of "Hypertension" Sodium-glucose Co-transporter 2 Inhibitors and Blood Pressure Reduction among Patients with Diabetes, Cardiovascular Disease, Chronic Kidney Disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1